A look back at Merck's Schering-Plough buyout; Cerulean raises $40M;

@FierceBiotech: EuroBiotech: Woodford: It's a bubble, Pfizer-backed IO player plans IPO, UniQure cashes in on Bristol deal. More | Follow @FierceBiotech

@JohnCFierce: Eisai cuts follow GlaxoSmithKline, Amgen, Merck, Sanofi, Pfizer, AstraZeneca, Shire, etc... Over 4 months. More | Follow @JohnCFierce

@DamianFierce: ICYMI: The thrilling conclusion to #FierceMadness and why I've had "One Shining Moment" stuck in my head all day. Winner | Follow @DamianFierce

> In 2009, when Merck ($MRK) paid roughly $50 billion for Schering-Plough, the company touted "5 stars" in its pipeline with blockbuster potential. The Wall Street Journal takes a look at just how that worked out. Story

> Cerulean Pharma ($CERU) raised about $40 million in a stock offering, moving more than 6.7 million shares as it works through mid-stage trials on its lead cancer therapy. More

Medical Device News

@FierceMedDev: Biocartis joins forces with Microbiome for quick sepsis test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA finalizes accelerated approval pathway for critical devices, aims to get med tech to market faster. Article | Follow @VarunSaxena2

@EmilyWFierce: Diagnosing Winnie the Pooh characters from the DSM. Just your typical Friday. | Follow @EmilyWFierce

> Pryor Medical gears up for rollout of military-inspired catheter. More

> Report: Demise of NeuroControl a cautionary tale of 'Orphan Markets' for devicemakers. Story

> Startup receives $20M in funding to test its leadless pacemaker. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaManufacturing: Chinese drugmaker to build $60M API plant. News | Follow @FiercePharma

@EricPFierce: Supply chain slip results in expired Pfizer birth control pills being sold in Canada. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Eisai to shed 450 jobs as it pares down U.S. workforce by one-fourth. News | Follow @CarlyHFierce

> Vertex Kalydeco combo could run payers $10M-plus per life, PBM figures. More

> Will Mylan's $29B bid spur other Perrigo suitors to enter the fray? Story

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.